# EDGAR Filing Document

**Accession Number:** 0000315545
**File Stem:** 0001641172-25-015520
**Filing Date:** 2025-6
**Character Count:** 5761
**Document Hash:** 9d566a532baae0bef3b9bf565f481f16
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-015520.hdr.sgml**: 20250618

**ACCESSION NUMBER**: 0001641172-25-015520

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 32

**CONFORMED PERIOD OF REPORT**: 20250618

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250618

**DATE AS OF CHANGE**: 20250618

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PROVECTUS BIOPHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0000315545
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 900031917
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36457
- **FILM NUMBER:** 251055257

**BUSINESS ADDRESS:**
- **STREET 1:** 800 S. GAY STREET
- **STREET 2:** SUITE 1610
- **CITY:** KNOXVILLE
- **STATE:** TN
- **ZIP:** 37929
- **BUSINESS PHONE:** (866) 594-5999

**MAIL ADDRESS:**
- **STREET 1:** 800 S. GAY STREET
- **STREET 2:** SUITE 1610
- **CITY:** KNOXVILLE
- **STATE:** TN
- **ZIP:** 37929

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PROVECTUS PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20020417

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZAMAGE DIGITAL IMAGING INC
- **DATE OF NAME CHANGE:** 20011126

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SPM GROUP INC
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 18, 2025**

**PROVECTUS BIOPHARMACEUTICALS, INC.**

(Exact name of registrant as specified in charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36457** | **90-0031917** |
| (State or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |

---

**800 S. Gay Street, Suite 1610, Knoxville, Tennessee 37929**

(Address of Principal Executive Offices) (Zip Code)

**(866) 594-5999**

(Registrant's Telephone Number, Including Area Code)

**N/A**

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<u>see</u> General Instruction A.2 below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01. Regulation FD Disclosure.**

During its annual meeting of stockholders to be held on June 18, 2025, Provectus Biopharmaceuticals, Inc. (the "Company") will provide an update about the Company's clinical development, regulatory affairs, drug discovery, manufacturing, intellectual property, business development, and corporate development activities.

A copy of the Company's 2025 Annual Meeting of Stockholders presentation slides is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

Pursuant to the rules and regulations of the Securities and Exchange Commission, the information in this Item 7.01 disclosure, including Exhibit 99.1 and information set forth therein, is deemed to have been furnished and shall not be deemed to be "filed" under the Securities Exchange Act of 1934, as amended.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| Exhibit<br> Number | Description |
| 99.1 | [2025 Annual Meeting of Stockholders presentation slides](ex99-1.htm) |
| 104 | Cover Page Interactive Date File (the cover page XBRL tags are embedded within the inline XBRL document). |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 18, 2025

---

| | |
|:---|:---|
| **PROVECTUS BIOPHARMACEUTICALS, INC.** | **PROVECTUS BIOPHARMACEUTICALS, INC.** |
| By: | */s/ Heather Raines* |
|  | Heather Raines |
|  | Chief Financial Officer (Principal Financial Officer) |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

![](ex99-1_002.jpg)

![](ex99-1_003.jpg)

![](ex99-1_004.jpg)

![](ex99-1_005.jpg)

![](ex99-1_006.jpg)

![](ex99-1_007.jpg)

![](ex99-1_008.jpg)

![](ex99-1_009.jpg)

![](ex99-1_010.jpg)

![](ex99-1_011.jpg)

![](ex99-1_012.jpg)

![](ex99-1_013.jpg)

![](ex99-1_014.jpg)

![](ex99-1_015.jpg)

![](ex99-1_016.jpg)

![](ex99-1_017.jpg)

![](ex99-1_018.jpg)

![](ex99-1_019.jpg)